# Kenai Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kenai-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.kenaitx.com/
- Total disclosed funding: $85M
- Latest round: Series A (Feb 29, 2024)
- Investors on record: 5

## About

Based in California, US, and founded in 2022 by co-founders Dr. Howard Federoff and Dr. Jeffrey Kordower, Kenai Therapeutics, Inc. formally known as RYNE Biotechnology, Inc., operates as a provider of neuron replacement cell therapies for neurological disorders using induced pluripotent stem cell (iPSC) technology. In February 2024, Kenai Therapeutics, Inc. raised USD 82 million in series A funding co-led by Alaska Permanent Fund Corporation, Cure Ventures, and The Column Group, with participation from Euclidean Capital and Saisei Ventures. As of March 2026, the company is led by its CEO, Nick Manusos.

The company provides a wide range of dopamine neuron replacement therapy products, including RNDP-001, an iPSC dopamine progenitor for Parkinson’s disease treatment; RNDP-002 for mild to severe rapid-progressing Parkinson’s disease; and RNDP-003 for young-onset Parkinson’s disease. Additionally, the firm offers preclinical and discovery programs using gene-modified iPSC technology.

The company plans to use its proceeds from February 2024 funding to complete clinical proof-of-concept trials for RNDP-001 in the treatment of Parkinson’s disease.

## Funding rounds

- Series A, Feb 29, 2024, $82M — Alaska Permanent Fund Corporation, The Column Group, Euclidean Capital, Cure Ventures, Saisei Ventures
- Seed, Jun 13, 2022, $3M — Saisei Ventures

## Investors

- Saisei Ventures (https://capitalatlas.ai/funds/saisei-ventures) — Seed, Series A
- Alaska Permanent Fund Corporation — Series A
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A
- Euclidean Capital — Series A
- Cure Ventures (https://capitalatlas.ai/funds/cure-ventures) — Series A